AMO Pharma makes three new appointments

All have widespread experience in the pharmaceutical industry

AMO Pharma, a privately held biopharmaceutical company focusing on debilitating diseases with limited or no treatment options, has welcomed Joseph Horrigan as Chief Medical Officer; Alison McMorn as Vice President of Clinical Operations; and Bernard Kiernan as Head of Pharmaceutical Sciences and Manufacturing.

Dr Horrigan comes to AMO Pharma with more than two decades of experience in the pharmaceutical industry and as a paediatric neuropsychiatrist.

Prior to joining AMO Pharma, he held multiple leadership positions in pharmaceuticals and medical research. Most recently he led clinical development programmes in neurodevelopmental disorders at Neuren Pharmaceuticals. He also co-founded and led the company-wide Medicines for Children Advisory Network at GlaxoSmithKline and was Assistant Vice President and Head of Medical Research at Autism Speaks.

McMorn has an extensive background in managing global clinical development programmes and most recently was Director of Clinical Programmes at Shire Pharmaceuticals.

Kiernan has more than 20 years of experience in pharmaceuticals and joins the team from Shire Pharmaceuticals where he was Director for Product Development in global pharmaceutical sciences.

You may also like

Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Packaging

Dual-chamber packaging systems as a simplification factor in the supply chain

Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
Regulatory

Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi

The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
Subscribe now